Gastrointestinal

Pancreatic cysts: surveillance and resection criteria

Clinical Overview and When to Suspect Pancreatic Cysts

— Serous cystadenoma (SCA): Almost always benign; central scar, "honeycomb" microcystic appearance.

— Mucinous cystic neoplasm (MCN): Premalignant; middle-aged women, body/tail, no duct communication, ovarian-type stroma.

— Intraductal papillary mucinous neoplasm (IPMN): Premalignant; communicates with the duct. Main-duct (MD-IPMN), branch-duct (BD-IPMN), or mixed.

— Solid pseudopapillary neoplasm: Young women, low-grade malignant.

— Pseudocyst: Post-pancreatitis, no epithelial lining, not neoplastic.

— New-onset diabetes after age 50 with a pancreatic lesion

— Obstructive jaundice with a cyst in the head

— Acute pancreatitis without gallstones/alcohol — consider underlying IPMN

— Weight loss, steatorrhea, or back pain with a known cyst

Board pearl: A cyst that communicates with the main pancreatic duct is an IPMN until proven otherwise — this single feature drives the entire surveillance algorithm. Pseudocysts require a history of pancreatitis — without it, do not anchor on "pseudocyst."

Definition: Fluid-filled lesions of the pancreas, increasingly detected incidentally on cross-sectional imaging obtained for unrelated indications (abdominal pain, trauma, CT for nephrolithiasis). Prevalence rises with age — up to 15% on MRI in patients >70.

Why Step 3 cares: The exam tests your ability to triage an incidental pancreatic cyst into surveillance vs EUS vs resection without over- or under-treating. Pancreatic adenocarcinoma carries a 5-year survival <12%, but most cysts are benign or low-risk — discrimination is everything.

Major cyst categories:

When to suspect a worrisome cyst:

Initial step when a cyst is found incidentally: Obtain a dedicated pancreas-protocol MRI/MRCP (or pancreas-protocol CT) to characterize size, septations, mural nodules, main pancreatic duct (MPD) diameter, and duct communication.

Presentation Patterns and Key History

— Obstructive jaundice (painless or painful) — head-of-pancreas lesion compressing CBD

— New-onset or worsening diabetes after age 50, especially within 1 year of cyst detection

— Unexplained acute pancreatitis — particularly recurrent episodes without gallstones, alcohol, or hypertriglyceridemia → suspect IPMN obstructing the duct with mucin

— Steatorrhea / weight loss — exocrine insufficiency from ductal obstruction

— Epigastric or back pain — late finding, often suggests invasion

— Prior episodes of pancreatitis (pseudocyst vs MCN/IPMN)

— Alcohol use, gallstones, hypertriglyceridemia, prior ERCP

— Family history of pancreatic, breast, ovarian, melanoma, colon cancer — screens for BRCA1/2, Lynch, Peutz-Jeghers, FAMMM, hereditary pancreatitis (PRSS1)

— Smoking and obesity (modifiable risk factors)

— Prior abdominal imaging — has the cyst grown? Stability over years is reassuring

— MCN: Woman, 40s–50s, body/tail, no duct communication

— BD-IPMN: Older man or woman, head/uncinate, "cluster of grapes"

— MD-IPMN: Older patient, diffuse MPD dilation, mucin extrusion from ampulla on ERCP

— Solid pseudopapillary: Woman in her 20s–30s

— SCA: Older woman, body/tail, microcystic

Step 3 management: When a cyst is found incidentally, always ask about prior cross-sectional imaging — a stable cyst over 5+ years dramatically lowers concern, while interval growth >2.5 mm/year is a worrisome feature triggering EUS-FNA.

Key distinction: Acute pancreatitis with no identifiable cause in an older adult is an IPMN screen, not just "idiopathic pancreatitis."

Most common presentation: Asymptomatic, incidental finding on imaging done for another reason. Roughly 70–80% of pancreatic cysts identified today are incidentalomas.

Symptomatic clues that raise concern for malignancy or high-risk cyst:

History elements to extract on Step 3:

Demographic patterns that anchor the diagnosis:

Physical Exam Findings (and Risk Assessment)

— Scleral icterus / jaundice — biliary obstruction from a head-of-pancreas cyst or invasive component; mandates urgent workup (MRCP, EUS, CA 19-9)

— Courvoisier sign — palpable, nontender gallbladder with jaundice — classically points to malignant distal biliary obstruction

— Cachexia, temporal wasting, sarcopenia — concerning for invasive carcinoma arising from IPMN/MCN

— Epigastric tenderness or palpable mass — large cyst, pseudocyst, or invasive tumor

— Migratory thrombophlebitis (Trousseau syndrome) — paraneoplastic in pancreatic adenocarcinoma

— Virchow node (left supraclavicular), Sister Mary Joseph nodule (periumbilical), Blumer shelf (rectal) — metastatic disease

— Peutz-Jeghers: mucocutaneous pigmentation → increased pancreatic cancer risk

— FAMMM: atypical nevi → CDKN2A mutation, pancreatic cancer screening indicated

— High-risk stigmata (per Fukuoka/Kyoto guidelines): obstructive jaundice with cystic head lesion, enhancing mural nodule ≥5 mm, MPD ≥10 mm, positive cytology for high-grade dysplasia/cancer

— Worrisome features: cyst ≥3 cm, thickened enhancing walls, MPD 5–9 mm, non-enhancing mural nodule, abrupt duct caliber change with distal atrophy, lymphadenopathy, CA 19-9 ↑, growth ≥2.5 mm/year

Board pearl: Courvoisier + painless jaundice + weight loss in an older patient with a pancreatic head cyst = invasive IPMN or pancreatic adenocarcinoma until disproven — go straight to EUS with FNA and staging CT.

General appearance: Most patients with pancreatic cysts have a completely normal physical exam. The exam is used to screen for complications, not to make the diagnosis.

Findings suggesting advanced disease or complication:

Skin/mucocutaneous clues to syndromic disease:

Vital signs: Usually normal. In a bleeding pseudocyst or ruptured cyst, tachycardia and hypotension may appear — rare but life-threatening. Fever suggests infected pseudocyst or cholangitis if biliary obstruction is present.

Risk assessment beyond the exam (the real Step 3 question):

Diagnostic Workup — Initial Labs and Imaging

— CBC, CMP — assess for anemia (chronic bleeding), elevated bilirubin/alkaline phosphatase (biliary obstruction)

— Lipase — elevated in active or recent pancreatitis; helps identify pseudocyst etiology

— HbA1c / fasting glucose — new-onset diabetes is a worrisome feature

— CA 19-9 — not a screening test, but elevation (>37 U/mL) in a cyst patient is a worrisome feature that prompts EUS-FNA; also useful for trending. Falsely low in Lewis antigen-negative patients (~5–10%)

— CEA in serum is NOT useful — CEA matters in cyst fluid, not blood

— Preferred for characterization and surveillance because of no radiation and superior soft-tissue/duct detail

— Defines: cyst size, septations, mural nodules, duct communication, MPD diameter, multifocality

— MRCP shows "cluster of grapes" appearance of BD-IPMN and diffuse MPD dilation of MD-IPMN

— Use when MRI contraindicated (pacemaker, severe claustrophobia, GFR issues with gadolinium)

— Better for calcifications: central stellate scar with calcification = serous cystadenoma; peripheral eggshell calcification = MCN with malignancy risk

— SCA: microcystic, central scar

— MCN: unilocular or macrocystic, body/tail, peripheral calcification, no duct communication

— BD-IPMN: grape cluster, duct communication

— MD-IPMN: diffusely dilated MPD ≥5 mm without obstruction

Step 3 management: When an incidental cyst is reported on abdominal CT done for another reason, the next best step is dedicated MRI/MRCP — not repeat CT, not EUS, not CA 19-9 alone.

Initial laboratory studies:

First-line imaging — pancreas-protocol MRI with MRCP:

Alternative — pancreas-protocol CT (multiphase):

Transabdominal US: Limited utility; bowel gas obscures the pancreas. Useful only as a screening incidental finding.

Imaging features by cyst type:

Diagnostic Workup — EUS, FNA, and Cyst Fluid Analysis

— Cyst ≥3 cm without high-risk stigmata

— Enhancing mural nodule <5 mm

— Thickened/enhancing cyst wall

— MPD 5–9 mm

— Abrupt caliber change with distal parenchymal atrophy

— Growth rate ≥2.5 mm/year

— Elevated serum CA 19-9

— New-onset diabetes

— Symptoms attributable to the cyst

— CEA:

— >192 ng/mL → mucinous cyst (MCN or IPMN); does NOT indicate malignancy, only mucinous lineage

— <5 ng/mL → favors serous cystadenoma or pseudocyst

— Amylase:

— High → duct communication → IPMN or pseudocyst

— Low → MCN or SCA

— Cytology: Definitive for high-grade dysplasia or invasive carcinoma; sensitivity is limited (~50%) due to scant cellularity

— Molecular markers:

— KRAS / GNAS mutations → IPMN (GNAS is highly specific)

— KRAS only → MCN

— VHL → serous cystadenoma

— CTNNB1 → solid pseudopapillary neoplasm

— TP53, SMAD4, CDKN2A mutations → high-grade dysplasia or invasive disease

Key distinction: CEA tells you mucinous vs non-mucinous; amylase tells you ductal communication; cytology and molecular markers tell you malignant potential. All three together — not one in isolation — drive resection decisions.

Board pearl: Don't FNA a suspected serous cystadenoma with classic central scar — risk outweighs benefit when imaging is diagnostic.

Endoscopic ultrasound (EUS) with fine-needle aspiration (FNA): Reserved for cysts with worrisome features or high-risk stigmata, indeterminate cysts after MRI, or cysts where management decisions hinge on cyst type or grade of dysplasia.

Indications for EUS-FNA:

Cyst fluid analysis — the high-yield panel:

String sign at EUS (mucin stretches between forceps) → mucinous cyst

Confocal laser endomicroscopy / through-the-needle biopsy: Emerging adjuncts at expert centers.

Risk Stratification and Surveillance vs Resection Logic

— Identify any high-risk stigmata → resection (surgical consultation)

— Identify any worrisome features → EUS-FNA to refine risk

— None of the above → size- and type-based surveillance

— Obstructive jaundice with pancreatic head cystic lesion

— Enhancing mural nodule ≥5 mm

— Main pancreatic duct ≥10 mm

— Cytology with high-grade dysplasia or invasive carcinoma

— Cyst ≥3 cm

— Enhancing mural nodule <5 mm

— Thickened/enhancing walls

— MPD 5–9 mm

— Abrupt MPD caliber change with distal atrophy

— Lymphadenopathy

— Elevated CA 19-9

— Growth ≥2.5 mm/year

— New-onset diabetes

— Pancreatitis attributable to cyst

— MD-IPMN or mixed-type IPMN in surgical candidates (high malignancy risk, up to 60%)

— MCN ≥4 cm, symptomatic MCN, or MCN with mural nodules

— Solid pseudopapillary neoplasm (always)

— Cystic neuroendocrine tumor

— <1 cm: MRI every 2 years × up to 10 years

— 1–2 cm: MRI yearly × 2, then every 2 years

— 2–3 cm: MRI/EUS every 6–12 months

— Many guidelines recommend continuing surveillance until the patient is no longer a surgical candidate

Step 3 management: A 1.2-cm incidental BD-IPMN in a 65-year-old with no worrisome features → MRI/MRCP surveillance, not EUS, not resection. Over-resection of low-risk cysts is a tested wrong answer because Whipple mortality is 2–5%.

The fundamental Step 3 decision tree for an incidental pancreatic cyst:

High-risk stigmata (mandate resection in surgical candidates):

Worrisome features (warrant EUS-FNA):

Resect regardless of size:

Surveillance (BD-IPMN without worrisome features):

Surveillance Protocols and Pharmacologic Considerations

— <1 cm: MRI every 2 years

— 1–2 cm: MRI every 1 year × 2 then every 2 years if stable

— 2–3 cm: Alternate MRI and EUS every 6–12 months

— >3 cm without worrisome features: EUS + MRI every 6 months

— Continue as long as the patient is a surgical candidate

— Reasonable to stop at age 75–80 or with significant comorbidities (life expectancy <10 years)

— CCS pearl: When advancing the clock on a CCS surveillance case, periodically reassess functional status, comorbid burden, and patient preference — these drive whether to continue imaging

— IPMN with low-grade dysplasia: MRI every 2 years

— IPMN with high-grade dysplasia or invasive: MRI every 6 months × 2 years, then yearly; consider CEA/CA 19-9

— MCN without invasive component: no further surveillance needed (curative resection)

— No proven role for chemoprevention in IPMN/MCN

— Smoking cessation — strongest modifiable risk factor for pancreatic cancer

— Glycemic control — new-onset diabetes raises pancreatic cancer risk; metformin is preferred in IPMN patients (observational data suggesting protective effect)

— Statin use — observational protective signal; do not start solely for cyst, but continue if otherwise indicated

— Avoid unnecessary ERCP in IPMN — risk of pancreatitis without diagnostic gain over MRCP/EUS

— Family history of pancreatic cancer in ≥2 first-degree relatives, or known BRCA1/2, Lynch, Peutz-Jeghers, FAMMM, hereditary pancreatitis → genetics consult and CAPS surveillance protocol

Board pearl: MRI/MRCP, not CT, is the surveillance imaging of choice — no cumulative radiation, better duct visualization, and validated across guidelines.

Surveillance is the "treatment" for most pancreatic cysts — there is no drug that shrinks them.

AGA, ACG, and International Consensus (Kyoto 2024) protocols converge on size-based MRI intervals for BD-IPMN without worrisome features:

Duration of surveillance:

Post-resection surveillance:

Pharmacologic considerations:

Genetic testing referral:

Surgical Resection — Procedures and Decision-Making

— Head/uncinate: Pancreaticoduodenectomy (Whipple) — removes head, duodenum, gallbladder, CBD, ± distal stomach. Mortality 2–5%, morbidity 30–50% (pancreatic fistula, delayed gastric emptying, anastomotic leak)

— Body/tail: Distal pancreatectomy ± splenectomy — splenectomy mandates pneumococcal, meningococcal, Hib vaccination ≥2 weeks pre-op

— Diffuse MD-IPMN: Total pancreatectomy — leaves patient with brittle diabetes and exocrine insufficiency; reserved for diffuse high-grade disease in select candidates

— Central/limited disease: Central pancreatectomy or enucleation — for small benign lesions to preserve parenchyma

— Staging CT chest/abdomen/pelvis

— Cardiac risk assessment (RCRI, stress testing if indicated)

— Nutritional optimization, smoking cessation ≥4 weeks pre-op

— Multidisciplinary tumor board review

— Frozen-section margin assessment — positive margin with high-grade dysplasia → extend resection

— Lymphadenectomy for malignancy

— NG decompression as needed, early mobilization, VTE prophylaxis

— Monitor drain amylase day 3 — drain amylase >3× serum = pancreatic fistula

— Pancreatic enzyme replacement (lipase 25,000–75,000 units per meal)

— Insulin for new diabetes; brittle control after total pancreatectomy

— Vaccinate post-splenectomy patients per ACIP

— Life expectancy <10 years, severe comorbidities, metastatic disease, patient preference for non-operative management

CCS pearl: After Whipple, advance the clock and check drain amylase on POD 3, start clears when tolerated, transition to enzyme replacement, schedule oncology follow-up at 2–4 weeks if pathology shows invasive disease — these orders are tested.

Step 3 management: Always confirm surgical candidacy before ordering EUS-FNA — if the patient cannot tolerate resection, FNA results won't change management.

Surgical options depend on cyst location:

Preoperative workup:

Intraoperative considerations:

Postoperative care (CCS-style management):

Who is NOT a surgical candidate?

Special Populations — Elderly and Renal/Hepatic Impairment

— Competing mortality is the dominant driver. A 78-year-old with a 1.5-cm stable BD-IPMN and CHF has a higher risk of dying from non-pancreatic causes than from cyst progression

— Step 3 management: Discuss stopping surveillance at age 75–80 or when life expectancy <10 years, regardless of cyst size, if patient is not a surgical candidate

— Shared decision-making documentation is tested — anxiety vs futility

— Functional assessment: gait speed, ADLs, frailty index matter more than chronologic age

— Gadolinium-based MRI contrast:

— eGFR ≥30: standard macrocyclic agents (gadobutrol, gadoteridol) are safe

— eGFR <30 or AKI: avoid linear agents; group II macrocyclic agents are generally acceptable with shared decision-making — NSF risk is exceedingly low with modern agents but still discussed

— CT contrast (iodinated): eGFR <30 → use isotonic IV hydration; weigh risk/benefit. Hold metformin around contrast if eGFR <30 or AKI

— Non-contrast MRCP is an option for surveillance when contrast is contraindicated — adequate for duct and cyst morphology

— Cirrhosis with portal hypertension: increased perioperative mortality for pancreatic resection

— Child-Pugh B/C or MELD >15 → generally not surgical candidates; favor surveillance

— Coagulopathy and varices complicate EUS-FNA — correct INR, platelets >50K before FNA

— New-onset diabetes after age 50 with a pancreatic cyst is a worrisome feature

— Post-resection diabetes (especially total pancreatectomy) requires endocrinology co-management — brittle, insulin-dependent, prone to hypoglycemia from loss of glucagon

Board pearl: In a frail elderly patient with a small stable BD-IPMN, the correct answer is often to stop surveillance, not continue indefinitely — guidelines explicitly endorse this when surgery is off the table.

Elderly patients (≥75 years):

Renal impairment:

Hepatic impairment:

Diabetes:

Special Populations — Pregnancy, Familial Syndromes, and Young Patients

— Pancreatic cysts in pregnancy are rare; usually incidental on ultrasound or non-contrast MRI for other indications

— MRI without gadolinium is safe in all trimesters; gadolinium is avoided (associated with stillbirth and neonatal outcomes in registry data)

— Defer EUS-FNA and elective resection until postpartum unless symptomatic or rapidly growing

— Symptomatic MCN or SPN in pregnancy: surgical resection ideally in second trimester if cannot wait

— ≥2 first-degree relatives with pancreatic cancer, or

— BRCA1/2, PALB2, ATM, Lynch (MMR), CDKN2A (FAMMM), STK11 (Peutz-Jeghers), PRSS1 (hereditary pancreatitis) carriers with ≥1 affected relative

— Screen starting age 50, or 10 years younger than the youngest affected relative (age 40 for Peutz-Jeghers, age 40 for hereditary pancreatitis, age 40 for CDKN2A)

— Annual MRI/MRCP ± EUS

— Refer to genetic counseling before testing

— Solid pseudopapillary neoplasm in young women — always resect; excellent prognosis

— Von Hippel-Lindau — multiple pancreatic serous cystadenomas, neuroendocrine tumors, RCC, pheochromocytomas, hemangioblastomas

— Recurrent pancreatitis with cysts → consider hereditary pancreatitis (PRSS1) — increased lifetime pancreatic cancer risk

Step 3 management: A 32-year-old woman with a 5-cm well-encapsulated cystic-solid pancreatic body lesion = solid pseudopapillary neoplasm → distal pancreatectomy, not surveillance. Order CTNNB1 if molecular workup is offered.

Key distinction: Family history of pancreatic cancer changes the threshold to screen — these patients enter dedicated CAPS programs, not generic surveillance.

Pregnancy:

Hereditary/familial pancreatic cancer syndromes — CAPS (Cancer of the Pancreas Screening) criteria:

Young patients (<40 years):

Pediatric considerations: Pancreatic cysts in children are nearly always pseudocysts (post-trauma, post-pancreatitis) or congenital. Neoplastic cysts are rare; SPN is the most common true cystic neoplasm.

Complications and Adverse Outcomes

— Malignant transformation — the central concern:

— MD-IPMN: up to 60% harbor high-grade dysplasia or invasive carcinoma

— BD-IPMN: 15–25% lifetime risk of high-grade dysplasia/cancer

— MCN: 10–15% harbor invasive carcinoma at resection

— SCA: <1% malignant potential

— Obstructive jaundice from head lesions compressing CBD

— Pancreatitis — mucin plugging the duct (IPMN)

— Diabetes — parenchymal destruction or new-onset signaling occult malignancy

— Steatorrhea / exocrine insufficiency — late finding

— Cyst rupture or hemorrhage — rare, presents as acute abdomen

— Infection — primarily pseudocysts

— EUS-FNA: pancreatitis (1–3%), bleeding, infection (rare with antibiotic prophylaxis controversial — most centers no longer give routine prophylaxis), perforation

— ERCP (rarely needed for cyst workup): post-ERCP pancreatitis (5–10%), cholangitis, bleeding, perforation

— Pancreatic fistula — most feared; drain amylase >3× serum on POD 3

— Delayed gastric emptying after Whipple (15–40%)

— Postpancreatectomy hemorrhage — sentinel bleed → urgent angiography

— Anastomotic leak, abscess, wound infection

— Brittle diabetes post-total pancreatectomy

— Exocrine insufficiency → lifelong pancreatic enzyme replacement

— Post-splenectomy sepsis (OPSI) — vaccinate, counsel on fever

— Patient anxiety, repeated imaging cost, incidental findings cascade

— Gadolinium retention concerns

— Procedure complications from FNA in low-risk cysts

Board pearl: A patient post-Whipple with POD 5 fever, leukocytosis, and elevated drain amylase → pancreatic fistula → CT, IR-guided drain placement, antibiotics, octreotide, NPO/TPN. Don't reoperate first.

CCS pearl: After splenectomy, give pneumococcal (PCV20 or PCV15+PPSV23), meningococcal ACWY + B, and Hib vaccines — counsel on fever precautions.

Cyst-related complications:

Procedural complications:

Surgical complications:

Surveillance-related harms (real, tested):

When to Escalate Care — Consult and Inpatient Triage

— Gastroenterology / advanced endoscopy: Any cyst with worrisome features needing EUS-FNA; all suspected IPMN/MCN for risk stratification

— Surgical oncology / HPB surgery: Cyst meeting resection criteria (high-risk stigmata, MD-IPMN, MCN ≥4 cm, SPN, symptomatic)

— Medical genetics: Family history meeting CAPS criteria or syndromic features

— Medical oncology: Invasive carcinoma on cytology or pathology

— Endocrinology: New-onset diabetes attributable to cyst or post-pancreatectomy

— Obstructive jaundice with cholangitis — fever, RUQ pain, jaundice (Charcot triad) — IV antibiotics, urgent ERCP for biliary drainage, then workup

— Acute pancreatitis thought due to IPMN — supportive care, NPO → early enteral nutrition, imaging once inflammation subsides

— Infected pseudocyst — IV antibiotics, drainage (endoscopic cystgastrostomy preferred over surgical)

— Cyst hemorrhage or rupture — hemodynamic resuscitation, IR, surgery

— Postoperative complications — fistula, sepsis, bleeding

— Severe pancreatitis with organ failure (BISAP ≥3, persistent SIRS)

— Septic shock from cholangitis or infected necrosis

— Hemorrhagic shock from sentinel bleed post-Whipple

— All cysts considered for resection

— All confirmed IPMN with high-grade dysplasia or invasive carcinoma

— Borderline resectable or locally advanced lesions

— Hospital discharge after EUS-FNA → ensure outpatient follow-up with results within 2 weeks

— Post-Whipple discharge → home with drain, enzyme replacement, follow-up with surgery in 1–2 weeks, oncology in 2–4 weeks if invasive

Step 3 management: A patient with a known pancreatic head cyst presenting with fever, jaundice, and RUQ pain = ascending cholangitis → IV antibiotics + urgent ERCP within 24 hours. Don't wait for MRCP if the diagnosis is clinically clear.

CCS pearl: Inpatient management of cyst-related cholangitis: blood cultures, broad-spectrum antibiotics (piperacillin-tazobactam), NPO, IV fluids, GI consult for ERCP, IR backup.

Outpatient referral indications:

Indications for inpatient admission:

ICU triage:

Multidisciplinary tumor board:

Transition-of-care touchpoints:

Key Differentials — Same-Category (Cystic Pancreatic Lesions)

— Older women, body/tail, microcystic with central stellate scar/calcification

— Cyst fluid: low CEA, low amylase, VHL mutation

— Benign — surveillance only; resect if symptomatic or >4 cm

— Middle-aged women (40s–50s), body/tail, unilocular, peripheral eggshell calcification, no duct communication

— Ovarian-type stroma on pathology (defining feature)

— Cyst fluid: high CEA, low amylase, KRAS mutation

— Premalignant — resect if ≥4 cm, symptomatic, or mural nodule; smaller asymptomatic MCN may be surveilled in select cases per newer guidelines

— Older patients, head/uncinate, "cluster of grapes", communicates with MPD

— Cyst fluid: high CEA, high amylase, KRAS + GNAS mutations

— Surveillance if no worrisome features; resect if high-risk stigmata

— Diffusely dilated MPD ≥5 mm, mucin extruding from ampulla

— High malignancy risk (~60%) — resect in surgical candidates

— Young women (20s–30s), well-encapsulated, mixed solid-cystic, CTNNB1 mutation

— Low-grade malignant — always resect, excellent prognosis

— Hypervascular rim, may secrete hormones (insulinoma, gastrinoma) or be nonfunctional

— Resect tumors >2 cm; consider surveillance for incidental <2 cm nonfunctional NETs

— Post-pancreatitis (≥4 weeks), no epithelial lining, high amylase, low CEA in fluid

— Drain if symptomatic, infected, or causing obstruction

Key distinction: CEA + amylase + KRAS/GNAS triangulate cyst type. GNAS is highly specific for IPMN. Ovarian stroma on histology defines MCN.

Board pearl: Microcystic + central scar + older woman = serous cystadenoma — surveillance, not resection.

Serous cystadenoma (SCA):

Mucinous cystic neoplasm (MCN):

IPMN — branch-duct (BD-IPMN):

IPMN — main-duct (MD-IPMN):

IPMN — mixed-type: Behaves like MD-IPMN; resect

Solid pseudopapillary neoplasm (SPN):

Cystic pancreatic neuroendocrine tumor:

Pseudocyst:

Lymphoepithelial cyst, retention cyst, hydatid cyst: Rare mimics

Key Differentials — Solid and Extra-Pancreatic Mimics

— Solid mass with central necrosis can mimic a cyst

— Highly elevated CA 19-9, weight loss, obstructive jaundice, vascular invasion

— Workup: pancreas-protocol CT, EUS-FNA of solid component, staging

— Calcifications, atrophic parenchyma, dilated irregular ducts ("chain of lakes")

— Pseudocysts can complicate this picture

— History of alcohol use, recurrent pancreatitis

— "Sausage-shaped" pancreas, diffuse enlargement, elevated IgG4, responds to steroids

— Can mimic malignancy; biopsy to confirm before resection

— Hypervascular, may be functional (insulinoma, gastrinoma, glucagonoma, VIPoma, somatostatinoma) or nonfunctional

— MEN1 association

— Renal cell carcinoma (classic, can be solitary and resectable), melanoma, lung, breast

— Always ask about prior cancer history

— Duplication cyst of duodenum/stomach

— Adrenal cyst or pseudocyst

— Mesenteric cyst, lymphangioma

— Choledochal cyst (Todani classification) — biliary, not pancreatic

— Splenic cyst or accessory spleen with cystic change

— Renal cyst abutting pancreas (especially upper pole)

— Splenic artery aneurysm or pseudoaneurysm — never FNA a vascular lesion; contrast imaging identifies

— Portal vein cavernous transformation

Board pearl: Before EUS-FNA of any pancreatic "cyst," confirm it is not a pseudoaneurysm or vascular structure with contrast-enhanced imaging — needling a splenic artery pseudoaneurysm is catastrophic.

Key distinction: A "pancreatic mass" with prior renal cell carcinoma history = metastatic RCC until proven otherwise — different treatment and prognosis.

Pancreatic adenocarcinoma with cystic degeneration:

Pancreatic ductal stricture from chronic pancreatitis:

Autoimmune pancreatitis (Type 1, IgG4-related):

Pancreatic neuroendocrine tumor (solid):

Acinar cell carcinoma: Rare; elevated lipase, lipase hypersecretion syndrome with subcutaneous fat necrosis and polyarthritis

Pancreatic lymphoma: Bulky lymphadenopathy, B symptoms; biopsy → chemo, not surgery

Metastases to pancreas:

Extra-pancreatic mimics on imaging:

Vascular mimics:

Secondary Prevention and Long-Term Plan

— Adhere to MRI/MRCP surveillance interval based on size and features

— Smoking cessation — most important modifiable risk factor for pancreatic cancer; offer varenicline, bupropion, NRT

— Alcohol moderation — heavy alcohol use accelerates pancreatic injury and cancer risk

— Weight management, exercise — obesity is an independent pancreatic cancer risk factor

— Diabetes screening annually — HbA1c; new-onset diabetes after age 50 in a cyst patient is a worrisome feature triggering EUS-FNA

— CA 19-9 trending may be done in some practices for high-risk patients, though not validated as standalone screening

— Pancreatic enzyme replacement (PERT) — lipase 25,000–75,000 units per meal; titrate to symptoms and stool steatocrit

— Fat-soluble vitamin (A, D, E, K) replacement if deficiency develops

— Insulin / diabetes management — endocrinology referral, especially after total pancreatectomy (brittle diabetes)

— Calcium and vitamin D for bone health in chronic exocrine insufficiency

— Post-splenectomy vaccines (if distal pancreatectomy with splenectomy): pneumococcal, meningococcal ACWY + B, Hib; annual influenza; counsel on fever precautions

— PPI if reflux post-Whipple

— Genetic counseling and CAPS surveillance if family history qualifies

— Hereditary syndrome surveillance for breast, ovarian, colon, melanoma, etc.

— Routine age-appropriate cancer screening (colon, breast, lung as applicable)

— Influenza, COVID-19, pneumococcal vaccines per ACIP

— Low-grade dysplasia: MRI every 2 years

— High-grade dysplasia: MRI every 6 months × 2 years then yearly

— Invasive carcinoma: oncology-driven protocol (CA 19-9, CT, every 3–6 months)

Step 3 management: Smoking cessation counseling at every visit is the single most impactful intervention you can document — exam-tested as the highest-yield modifiable risk factor.

For patients under surveillance (no resection):

For patients post-resection:

For all patients:

Surveillance after resection (per AGA/IAP):

Follow-Up, Monitoring Parameters, and Patient Counseling

— Symptom review: jaundice, weight loss, new abdominal pain, steatorrhea, polyuria/polydipsia

— Imaging review: cyst size, mural nodules, MPD, multifocality, growth rate

— Labs: HbA1c annually; CA 19-9 in select cases

— Lifestyle counseling: smoking, alcohol, weight, exercise

— Shared decision-making about continuing vs stopping surveillance

— ≥2.5 mm/year = worrisome feature → EUS-FNA

— Any new mural nodule, MPD dilation, or wall thickening → EUS-FNA or surgery

— Surgical clinic at 2 weeks for wound check, drain management

— Pathology review at 2–4 weeks — drives oncology referral

— Oncology if invasive disease or high-grade dysplasia

— Endocrinology for new diabetes

— Nutrition for PERT titration

— Most pancreatic cysts are benign or low-risk — frame surveillance as risk reduction, not cancer diagnosis

— Surveillance does not eliminate cancer risk; report new jaundice, unintentional weight loss, persistent abdominal pain, new diabetes between visits

— Genetic testing is voluntary; results may affect insurance/family

— Whipple/distal pancreatectomy are major operations — discuss morbidity (30–50%) and mortality (2–5%) honestly

— Patient no longer surgical candidate

— Life expectancy <10 years

— Patient preference after informed discussion

— Document the decision clearly

— Avoid surveillance overuse in low-risk small stable cysts

— Avoid CT-based surveillance when MRI is feasible (radiation exposure over decades)

CCS pearl: On the CCS exam, an advancing-clock surveillance encounter should include vital signs, HbA1c, MRI/MRCP, smoking cessation counseling, and reassessment of surgical candidacy — that complete order set scores points.

Board pearl: Stability for 5+ years in a small BD-IPMN dramatically reduces malignant transformation risk; some guidelines allow extending surveillance intervals.

Surveillance visit components:

Growth thresholds that change management:

Post-resection follow-up:

Patient counseling pearls:

When to stop surveillance:

Quality and value-based care:

Ethical, Legal, and Patient Safety Considerations

— When a cyst is discovered on imaging done for an unrelated reason, the ordering clinician has a duty to disclose, contextualize, and arrange follow-up — even if the cyst is small and low-risk

— Failure to communicate incidental findings is a leading source of malpractice claims; document the conversation and follow-up plan

— Discuss risks: pancreatitis (1–3% for FNA), bleeding, infection, perforation

— For Whipple: explicitly disclose mortality (2–5%) and major morbidity (30–50%)

— Discuss alternatives, including continued surveillance

— In elderly or frail patients, document the conversation about competing mortality and the choice to discontinue imaging — anchoring against family pressure to "do something" is a Step 3 ethics theme

— Respect autonomy: a competent patient may choose to continue or discontinue surveillance

— Pre-test counseling required; results affect family members

— GINA (Genetic Information Nondiscrimination Act) protects against health insurance and employment discrimination but not life, disability, or long-term care insurance

— Document informed consent prior to germline testing

— Post-EUS-FNA discharge: ensure results are communicated within 2 weeks; track callbacks

— Post-Whipple discharge: medication reconciliation (PERT, insulin, PPI, analgesics), drain instructions, red-flag symptoms

— Surveillance handoff when transferring care: send prior imaging, growth trajectory, prior FNA results

— Over-surveillance of low-risk cysts contributes to low-value care; align with guideline thresholds

Step 3 management: A 79-year-old with mild dementia and a stable 1.2-cm BD-IPMN — the family wants annual MRI; the patient says she does not. Respect patient autonomy if she retains decisional capacity; document the conversation and stop surveillance.

Board pearl: Failure to communicate an incidental pancreatic cyst is a sentinel patient-safety event — closed-loop communication is mandatory.

Incidentaloma disclosure and the "cascade of testing":

Informed consent for EUS-FNA and resection:

Shared decision-making about stopping surveillance:

Genetic testing ethics:

Transition-of-care safety:

Mandatory reporting / public health: Not applicable to cyst care directly, but incidental findings of substance abuse, intimate partner violence, or impaired driving from opioids in the perioperative period may trigger state-specific reporting obligations

Resource stewardship:

High-Yield Associations and Rapid-Fire Facts

— Older woman + microcystic + central scar → serous cystadenoma → surveillance

— Middle-aged woman + body/tail + unilocular + ovarian stroma → MCN → resect if ≥4 cm/symptomatic

— Older patient + head + cluster of grapes + duct communication → BD-IPMN → surveillance vs FNA

— Diffuse MPD dilation + mucin at ampulla → MD-IPMN → resect

— Young woman + well-encapsulated mixed solid-cystic → SPN → resect

— CEA >192 = mucinous (MCN or IPMN)

— CEA <5 = serous or pseudocyst

— High amylase = duct communication (IPMN or pseudocyst)

— KRAS + GNAS = IPMN (GNAS specific)

— KRAS alone = MCN

— VHL = SCA

— CTNNB1 = SPN

— Obstructive jaundice + cystic head lesion

— Enhancing mural nodule ≥5 mm

— MPD ≥10 mm

— Cytology with HGD or invasive carcinoma

— Cyst ≥3 cm, mural nodule <5 mm, wall thickening, MPD 5–9 mm, abrupt caliber change with atrophy, lymphadenopathy, ↑CA 19-9, growth ≥2.5 mm/year, new-onset diabetes, cyst-related pancreatitis

— VHL → multiple SCAs, pNETs, RCC, hemangioblastoma, pheo

— Peutz-Jeghers (STK11) → pancreatic, breast, GI cancers

— FAMMM (CDKN2A) → melanoma + pancreatic

— BRCA1/2, PALB2, ATM, Lynch → CAPS surveillance starting age 50 or 10 years prior

— Hereditary pancreatitis (PRSS1) → cysts and high lifetime cancer risk

— Whipple mortality 2–5%, morbidity 30–50%

— Pancreatic fistula: drain amylase >3× serum on POD 3

Board pearl: GNAS mutation = IPMN, ovarian stroma = MCN, central scar = SCA, CTNNB1 = SPN — four single-shot diagnostic hooks.

Cyst-type quick recognition:

Cyst fluid markers (memorize cold):

High-risk stigmata (mandate resection):

Worrisome features (warrant EUS-FNA):

Syndromic associations:

Surgery key numbers:

Imaging principle: MRI/MRCP > CT for cyst surveillance — no radiation, better ducts

Board Question Stem Patterns

— "A 62-year-old woman has a 1.2-cm cystic lesion in the pancreatic head on CT obtained for nephrolithiasis. She is asymptomatic." → Next step: pancreas-protocol MRI/MRCP. Distractors: CT in 6 months, EUS-FNA, surgery.

— "BD-IPMN measuring 3.2 cm with a 3-mm enhancing mural nodule." → EUS-FNA (cyst ≥3 cm + nodule <5 mm = worrisome features). If nodule were ≥5 mm or MPD ≥10 mm → surgery.

— "Diffusely dilated MPD to 11 mm with mucin extruding from the major papilla on ERCP." → Surgical resection (MD-IPMN, high malignancy risk).

— "42-year-old woman with a 5-cm unilocular cyst in the pancreatic tail, peripheral eggshell calcification, no duct communication. CEA in fluid is elevated." → Distal pancreatectomy (MCN ≥4 cm).

— "70-year-old woman with a microcystic lesion and central stellate calcification." → Reassurance and surveillance — not resection.

— "28-year-old woman with a 5-cm well-encapsulated mixed solid-cystic mass in the body of the pancreas." → Distal pancreatectomy.

— "Patient 6 weeks after gallstone pancreatitis with a 4-cm cyst, lipase 80, persistent epigastric pain." → If asymptomatic, observe; if symptomatic/infected/obstructing → endoscopic cystgastrostomy.

— "65-year-old with known 1.5-cm BD-IPMN, now HbA1c 8.2% from 5.8% one year ago." → EUS-FNA (new-onset diabetes is a worrisome feature).

— "45-year-old with two first-degree relatives with pancreatic cancer." → Genetic counseling + CAPS surveillance with MRI/EUS.

— "82-year-old with multiple comorbidities and a stable 1-cm BD-IPMN × 6 years." → Discontinue surveillance.

Step 3 management: When unsure between EUS-FNA vs MRI vs surgery, anchor to the high-risk stigmata / worrisome features framework. Memorize the lists.

Pattern 1 — The incidentaloma:

Pattern 2 — The worrisome feature:

Pattern 3 — The MD-IPMN:

Pattern 4 — The MCN:

Pattern 5 — The serous cystadenoma:

Pattern 6 — The SPN:

Pattern 7 — The pseudocyst:

Pattern 8 — The new-onset diabetes:

Pattern 9 — The family history:

Pattern 10 — The elderly frail patient:

One-Line Recap

Pancreatic cysts are stratified by imaging features and cyst fluid analysis into surveillance vs EUS-FNA vs resection, with high-risk stigmata (jaundice + head cyst, mural nodule ≥5 mm, MPD ≥10 mm, malignant cytology) mandating surgery and worrisome features (size ≥3 cm, smaller nodule, MPD 5–9 mm, growth ≥2.5 mm/year, new diabetes, ↑CA 19-9) prompting EUS-FNA, while low-risk asymptomatic BD-IPMNs receive size-based MRI/MRCP surveillance until the patient is no longer a surgical candidate.

Board pearl: MRI/MRCP for surveillance, EUS-FNA for worrisome features, surgery for high-risk stigmata, and stop the clock when surgery is off the table — that single sentence covers ~80% of Step 3 pancreatic cyst questions.

Key distinction: Step 3 rewards calibrated under-treatment of low-risk cysts as much as it rewards timely escalation of high-risk ones — pancreaticoduodenectomy is not benign, and over-resection is a tested wrong answer.

Diagnose by imaging + fluid: MRI/MRCP characterizes cyst; EUS-FNA with CEA (mucinous if >192), amylase (duct communication if high), and molecular markers (GNAS = IPMN, KRAS alone = MCN, VHL = SCA, CTNNB1 = SPN) refines risk.

Always resect: MD-IPMN, mixed IPMN, MCN ≥4 cm or symptomatic, solid pseudopapillary neoplasm, any cyst with high-risk stigmata in a surgical candidate.

Always surveille (and don't FNA): Classic serous cystadenoma with central scar; small stable BD-IPMN without worrisome features.

Stop surveillance when the patient is no longer a surgical candidate, life expectancy is <10 years, or the patient declines after informed discussion — document shared decision-making.